Pancreatic cancer therapeutic composition and use of sijunzi decoction composition for making pancreatic cancer therapeutic composition

Abstract

This invention provides a pancreatic cancer treatment composition and the use of a Sijunzi decoction compound in the manufacture of a pancreatic cancer treatment composition. Specifically, this invention involves administering a pancreatic cancer treatment agent and a Sijunzi decoction compound to pancreatic cancer patients to treat pancreatic cancer and improve cancer cachexia, thereby achieving the effects of slowing pancreatic cancer tumor growth, alleviating pancreatic cancer cachexia, and reducing tumor immunosuppression.

Claims

1. A pancreatic cancer treatment composition comprising: A pancreatic cancer treatment agent; And a compound of Sijunzi Decoction, including ginseng extract, atractylodes macrocephala extract, poria cocos extract, licorice extract, ginger extract and jujube extract, wherein, after the pancreatic cancer treatment composition is administered to a pancreatic cancer patient, the pancreatic cancer treatment agent and the compound of Sijunzi Decoction provide a combined treatment effect for pancreatic cancer and cancer cachexia.

2. The pancreatic cancer treatment composition as described in claim 1, wherein, The pancreatic cancer treatment agents include leucovorin, 5-fluorouracil (5-FU), irinotecan, oxaliplatin, gemcitabine, capecitabine, or any combination thereof.

3. The pancreatic cancer treatment composition as described in claim 1, wherein, The compound composition of Sijunzi Decoction is obtained by water extraction from a mixture of ginseng, atractylodes macrocephala, poria cocos, licorice, ginger, and jujube.

4. The pancreatic cancer treatment composition as described in claim 3, wherein, The weight ratio of the ginseng, atractylodes macrocephala, poria cocos, licorice, ginger, and jujube is (1.0 to 5.0): (1.0 to 5.0): (1.0 to 5.0): (1.0 to 2.0): (1.0 to 2.0): 1.

0.

5. The pancreatic cancer treatment composition as described in claim 3, wherein, The weight ratio of the pancreatic cancer treatment agent to the Sijunzi decoction complex is 1:1 to 10.

6. The pancreatic cancer treatment composition as described in any one of claims 1 to 5, wherein, The pancreatic cancer treatment agent and the Sijunzi decoction compound are packaged separately, forming a treatment unit and an adjuvant unit respectively.

7. The use of a Sijunzi decoction complex in the manufacture of a pancreatic cancer treatment composition, wherein, The pancreatic cancer treatment composition comprises: a pancreatic cancer treatment agent; and a Sijunzi decoction complex, including a ginseng extract, a white atractylodes extract, a poria cocos extract, a licorice extract, a ginger extract, and a jujube extract. The use includes administering the pancreatic cancer treatment composition to a pancreatic cancer patient, so that the pancreatic cancer treatment agent and the Sijunzi decoction complex provide a combined therapeutic effect, thereby slowing pancreatic cancer tumor growth, alleviating pancreatic cancer cachexia, and reducing tumor immunosuppression.

8. The use as described in claim 7, wherein, The pancreatic cancer treatment agent includes leucovorin, 5-fluorouracil (5-FU), irinotecan, oxaliplatin, gemcitabine, capecitabine, or any combination thereof; the Sijunzi decoction compound is obtained by water extraction from a mixture of ginseng, atractylodes macrocephala, poria cocos, licorice, ginger, and jujube.

9. The use as described in claim 7, wherein, The administration of the pancreatic cancer treatment composition includes: administering the pancreatic cancer treatment agent to the pancreatic cancer patient at a first time point, and repeatedly administering the Sijunzi Decoction compound to the pancreatic cancer patient multiple times between a second time point and a third time point, wherein the first time point is earlier than, later than, or the same as the second time point, and the third time point is later than the first time point and the second time point, wherein the third time point occurs within 1 to 6 days after the second time point, during which time the Sijunzi Decoction compound is repeatedly administered at least 1 to 6 times.

10. The use as described in claim 7, wherein, During the administration cycle completed between the first time point and the third time point, the effective dose of the pancreatic cancer treatment agent is 160 to 180 mg / kg, and the effective dose of the Sijunzi decoction compound is 160 to 1800 mg / kg.

Images